Columbia University Medical Center and New York-Presbyterian, in coordination with the Foundation for the National Institutes of Health Biomarkers Consortium, is launching a three-year research collaboration to develop new methods for analyzing digital images that track a patient’s response to cancer therapy.
A group of melanoma experts, joined by three advocacy groups focused on melanoma, has engaged FDA in a public discussion of the challenges of developing new drugs in the refractory setting and the role crossover can play in such trials.
